Vascular cell adhesion molecule 1 – Very late antigen-4 axis (VCAM-1 – VLA-4 axis)

The VCAM-1 – VLA-4 axis represents the critical molecular interaction between Vascular Cell Adhesion Molecule 1 (VCAM-1, also known as CD106) and the integrin Very Late Antigen-4 (VLA-4, or alpha-4-beta-1). VCAM-1 is an immunoglobulin-like adhesion molecule primarily expressed on the surface of vascular endothelial cells following activation by inflammatory cytokines (UniProt P19320). Its cognate receptor, VLA-4, is expressed on the surface of most leukocytes, including lymphocytes, monocytes, and eosinophils (UniProt P13612). This interaction is a fundamental step in the leukocyte adhesion cascade, mediating the firm attachment of immune cells to the vessel wall and their subsequent transendothelial migration into peripheral tissues (PubMed: 10490973). In pathological states, this axis is a major driver of chronic inflammation and autoimmune disease. In multiple sclerosis, the VCAM-1 – VLA-4 interaction facilitates the entry of pathogenic T-cells across the blood-brain barrier into the central nervous system, leading to neuroinflammation and demyelination (PubMed: 15548778). Similarly, it plays a key role in the recruitment of inflammatory cells to the intestinal mucosa in Crohn's disease and ulcerative colitis. Therapeutic targeting of this axis, most notably with the monoclonal antibody Natalizumab, blocks the alpha-4 subunit of VLA-4, thereby sequestering inflammatory cells within the systemic circulation and preventing tissue damage (StatPearls: NBK537263). However, long-term therapeutic blockade is associated with a significant risk of Progressive Multifocal Leukoencephalopathy (PML) due to the suppression of local immune surveillance in the brain (PubMed: 15958803).

Other names

CD106 – CD49d/CD29 axisVCAM-1 – Integrin alpha-4 beta-1 axisVCAM-1 – alpha-4-beta-1 interactionVCAM1 – ITGA4/ITGB1 axis

Antagonism of the VLA-4 integrin (specifically the alpha-4 subunit) or VCAM-1 to prevent leukocyte adhesion to the vascular endothelium and subsequent migration into inflamed tissues.